Filling a syringe

CP057 SR Bevacizumab

CP057 is a sustained released injection formulation of Bevacizumab, an anti-VEGF therapy for the treatment of Age-related Macular Degeneration (AMD).  Using the CriticalMix technology, CP057 is being developed as a once every three month injection.

AMD is the leading cause of blindness in the over 50’s.  It is caused by abnormal blood vessel growth near the macula of the retina.  Bleeding, leaking and scarring from these blood vessels eventually cause damage leading to impaired vision.  Anti-VEGF therapies are effective at delaying, halting or even reversing this visual loss, but require monthly injections to the eye.  These are disliked by patients and have the concomitant risk of serious eye problems such as infections.

CP057 SR Bevacizumab therefore offers a cost effective, safe and effective alternative to current therapies

CriticalMix Technology

CriticalMix rig

CriticalMix enables the manufacture of highly active sustained release depot products for bimonthly, monthly or less frequent injection.

Read more

CP024 Nasal GH

measuring height

CP024 has completed two Phase 1 clinical trials where our intranasal growth hormone has shown comparable activity to injection.

Read more

Dr Andy Lewis, Critical Pharmaceuticals
“Our competitors can make sustained release formulations of small molecular weight drugs, but they need to use a lot of solvents to do it. We realised that using solvents when making medicines to be given to patients creates a lot of problems for the manufacturers. Firstly, many of these solvents are very toxic, and without costly extraction procedures, residues can be left in the products. Proving to the regulators that these extraction procedures are effective is also costly and time consuming, so when you want to get your product to market as quickly as possible you would rather not have to do it. Secondly, disposing of large amounts of these solvents is also very expensive and carries with it environmental concerns. By using our CriticalMix™ technology we can formulate drugs in a dry state without using any solvents at all.”